Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Moderna, Inc.
Pfizer held the number one spot on the Scrip 100 on the strength of its COVID-19 products, while some others faced challenging financial comparisons in 2022 because of COVID-19 headwinds.
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.
UK life sciences sector leaders are pleased to have attracted Flagship Pioneering to invest in the country, as its CEO Noubar Afeyan emphasizes that its initial focus would be on early ‘experiments’ in innovation and cultural bridge-building.
Industry experts from Norstella, whose data and technologies support decision making from R&D through to market access, shared their worries going into 2024.
- Drug Delivery
- Antisense, Oligonucleotides
- Large Molecule
Drug Discovery Technologies
- Other Names / Subsidiaries
- Caperna LLC
- Moderna Therapeutics, Inc.
- Moderna LLC
- Newco LS18, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.